Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer

Welcome to APCCC 2021

ESMO 2021 Roundup

OncoAlert and ecancer - ESMO 2021 Day 5

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Disparities in myeloma: Closing the gap

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

ESMO President: What to watch for at ESMO 2021

OncoAlert and ecancer - ESMO 2021 preview

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM